Short-term efficacy and safety of lurasidone in the treatment of schizophrenia

L'Encéphale
Ludovic SamalinP-M Llorca

Abstract

Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration and in March 2014 by the European Medicines Agency for the treatment of schizophrenia. Like other second-generation antipsychotics, lurasidone is an antagonist of D2 dopamine and 5HT2A serotonin receptors, but differs from the other second-generation antipsychotics in its action profile for certain receptors. Lurasidone is the second-generation antipsychotic with the greatest affinity for 5HT7 receptors and has a low affinity for α1 and α2C-adrenergic and 5HT2C serotonin receptors, and no affinity for histaminergic H1 or muscarinic M1 receptors. Lurasidone has demonstrated its efficacy in several short-term studies in acute schizophrenia with significantly reducing total scores of Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) compared with placebo. Early improvement was observed by days 3-7 for the 80-160 mg/day doses. Two studies with several methodological limitations showed that lurasidone might be involved in the improvement of cognitive performance in schizophrenic patients. Post hoc analysis of four pooled short-term studies showed significantly better effects on improvi...Continue Reading

References

Nov 26, 2015·L'Encéphale·Ludovic SamalinP-M Llorca

Citations

Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony D Loebel
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananSchizophrenia Patient Outcomes Research Team (PORT)
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, Schizophrenia Consensus Group of British Association for Psychopharmacology
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony D Loebel
Jul 15, 2011·Therapeutics and Clinical Risk Management·Ludovic SamalinPierre-Michel Llorca
Jul 26, 2012·The Annals of Pharmacotherapy·Vineeta RisboodMatthew A Fuller
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Aug 21, 2012·Psychopharmacology·Masaaki OgasaJohn Guarino
Sep 17, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Philip D HarveyAntony D Loebel
Feb 14, 2014·BMJ : British Medical Journal·Elizabeth KuipersTim Kendall
May 2, 2014·Expert Review of Neurotherapeutics·Cecilio AlamoPilar García-García

Related Concepts

Antipsychotic Effect
Olanzapine
Schizophrenia
Clozapine
Ziprasidone
Hyperprolactinemia
Lurasidone
Bipolar Disorder
Isoindoles
Latuda

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

Therapeutics and Clinical Risk Management
Ludovic SamalinPierre-Michel Llorca
Neuropsychiatric Disease and Treatment
Young Sup WooWon-Myong Bahk
Neuropsychiatric Disease and Treatment
Tomomi TenjinNoboru Yamaguchi
Neuropsychiatric Disease and Treatment
Silvio CacciaAlessandro Nobili
© 2020 Meta ULC. All rights reserved